Hemogenyx Pharmaceuticals PLC
Research Hemogenyx Pharmaceuticals PLC (HEMO) on Bullrun: market cap GBX 4.63B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHEMO
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyGBX
- Market capGBX 4.63B
- Financial periodFY2025
- RevenueGBP 0
- Net income-GBP 9.76M
- Free cash flow-GBP 3.45M
Valuation Snapshot
latest market cap is GBX 4.63B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 0 | -GBP 9.76M | -GBP 3.45M | n/a | -1.71 | GBP 1.59M | GBP 2.00M | GBP 1.20M |
| FY2024 | GBP 0 | -GBP 5.62M | -GBP 4.15M | n/a | -1.81 | GBP 159.27K | GBP 2.62M | GBP 897.51K |
| FY2023 | GBP 0 | -GBP 6.69M | -GBP 6.22M | n/a | -2.37 | GBP 1.25M | GBP 2.95M | GBP 2.82M |
| FY2022 | GBP 0 | -GBP 3.98M | -GBP 3.34M | n/a | -2 | GBP 2.53M | GBP 3.42M | GBP 3.28M |
| FY2021 | GBP 0 | -GBP 5.10M | -GBP 3.45M | n/a | -2.8 | GBP 6.84M | GBP 10.15K | GBP 8.19M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-05 | GBX 4.63B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Hemogenyx Pharmaceuticals PLC
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hemogenyx Pharmaceuticals PLC's market cap?
Hemogenyx Pharmaceuticals PLC's market capitalization is GBX 4.63B.
What does Hemogenyx Pharmaceuticals PLC do?
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer in the United Kingdom and the United States. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia.